Extended 73‐month survival in an elderly patient with BRAF V600E‐mutated lung adenocarcinoma: A case report

BRAF is a mediator that activates the mitogen‐activated protein kinase pathway. A mutation in BRAF can cause abnormal pathway activation, leading to cell proliferation. In a Phase II study, the combination therapy of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib was found to be effe...

Full description

Saved in:
Bibliographic Details
Published in:Respirology case reports 2024-10, Vol.12 (10), p.e70040-n/a
Main Authors: Namba, Kensuke, Isobe, Kazutoshi, Wakabayashi, Hiroki, Ohashi, Ryogo, Sakurai, Hiromasa, Sakai, Daiki, Irie, Yusuke, Takashima, Kenta, Murakami, Yu, Kaneko, Kaichi, Hiruta, Nobuyuki, Matsuzawa, Yasuo
Format: Article
Language:English
Subjects:
BRAF V600E mutation
Case Report
Case reports
Combination therapy
dabrafenib/trametinib
Editing
elder
Kinases
Lung cancer
Medical prognosis
Metastasis
Mutation
non‐small cell lung cancer
Patients
Pleural effusion
Writing
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BRAF is a mediator that activates the mitogen‐activated protein kinase pathway. A mutation in BRAF can cause abnormal pathway activation, leading to cell proliferation. In a Phase II study, the combination therapy of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib was found to be effective in non‐small cell lung cancer (NSCLC) patients with the BRAF mutation. However, this study has limited efficacy and safety data for elderly patients. We present a case of a patient who started treatment at 87 years old and showed a good prognosis, remaining alive 73 months from the start of treatment with no significant adverse events. The patient also maintained a partial response (PR) according to RECIST 1.1 at the last follow‐up. This case suggests that the dabrafenib and trametinib combination therapy is safe and effective for elderly NSCLC patients with the BRAF mutation. We are reporting a case of an 87‐year‐old patient who underwent this treatment and had a favourable clinical outcome without any serious adverse events.
ISSN:2051-3380
2051-3380
DOI:10.1002/rcr2.70040